FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, finding sufficient shortcomings in post-market monitoring and pre-market notification to warrant a warning letter.
J&J and subsidiary McNeil Consumer Healthcare say they have come a long way in improving management of OTC pharma...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?